8-K: FutureTech II Acquisition Corp. Secures $5 Million Private Placement with Escrow Agreement

FutureTech II Acquisition Corp. finalizes a subscription agreement and escrow agreement with Yuantian Zhang for a $5 million private placement tied to a business combination.

Summary

• FutureTech II Acquisition Corp. entered into a Subscription Agreement with Yuantian Zhang on December 13, 2024, for a private placement of 1,000,000 shares of Class A Common Stock at $5.00 per share, totaling $5,000,000.
• The private placement is connected to a proposed business combination with Longevity Biomedical, Inc.
• On January 31, 2025, the company and the investor signed an escrow agreement dated January 23, 2025, to issue an additional 2,000,000 shares of Class A Common Stock as Escrow Shares.
• The Escrow Shares will be held for two years from the closing date and released to the investor if the closing price of the common stock is less than $7.50 per share immediately prior to the Escrow Release Date.
• The Escrow Agent will release a portion of the Escrow Shares to the Investor such that the aggregate value of all shares of Common Stock issued to the Investor at or before the Closing plus the value of the portion of the Escrow Property released to the Investor is equal to $7,500,000.
• If the aggregate value of all shares of Common Stock issued to the Investor at or before the Closing plus the value of the Escrow Property on the Escrow Release Date is less than $7,500,000, the Investor will be entitled to receive all of the Escrow Property but nothing more.

Sentiment

Score: 7

Explanation: The announcement is generally positive as it secures funding for the company, but the potential dilution from the escrow shares introduces some uncertainty.

Positives

• The $5 million private placement provides FutureTech II Acquisition Corp. with additional capital.
• The escrow agreement incentivizes the investor while protecting their investment if the stock price declines below $7.50.
• The funding is tied to a proposed business combination with Longevity Biomedical, Inc., potentially creating synergies and growth opportunities.

Negatives

• The potential issuance of 2,000,000 Escrow Shares could dilute existing shareholders if the stock price remains below $7.50 after two years.
• The release of Escrow Shares is contingent on the stock price performance, creating uncertainty for existing shareholders.

Risks

• The business combination with Longevity Biomedical, Inc. may not be successful, impacting the company's future prospects.
• The stock price may decline below $7.50, triggering the release of Escrow Shares and diluting existing shareholders.
• The investor may receive all of the Escrow Property but nothing more if the aggregate value of all shares of Common Stock issued to the Investor at or before the Closing plus the value of the Escrow Property on the Escrow Release Date is less than $7,500,000.

Future Outlook

The company is focused on completing the business combination with Longevity Biomedical, Inc. and managing the escrow agreement related to the private placement.

Industry Context

SPACs (Special Purpose Acquisition Companies) like FutureTech II Acquisition Corp. are increasingly common vehicles for companies to go public, and private placements are often used to secure additional funding in connection with these transactions.

Stakeholder Impact

• Shareholders may experience dilution if the Escrow Shares are released.
• The company's financial position is strengthened by the $5 million private placement.
• The business combination with Longevity Biomedical, Inc. could impact the company's future performance and shareholder value.

Next Steps

• Closing of the private placement.
• Consummation of the business combination with Longevity Biomedical, Inc.
• Management of the escrow agreement and potential release of Escrow Shares after two years.

Key Dates